Calcium sensitisers: Mechanisms of action and potential usefulness as inotropes

Cardiovascular Research

Volumn 36, Issue 1, 1997, Pages 10-20

  Lee, J A ^a   Allen, D G ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Calcium sensitisers; Cardiac muscle; Cardiotonic agents; Heart failure; Inotropic agents; Intracellular calcium

Indexed keywords

1,3,5,6 TETRAHYDRO 5 METHYL 6 PHENYL 3,6 METHANO 1,5 BENZODIAZOCINE 2,4 DIONE; 4,5 DIHYDRO 6 [4 (4 PYRIDYLAMINO)PHENYL] 3(2H) PYRIDAZINONE; 5 [1 (3,4 DIMETHOXYBENZOYL) 1,2,3,4 TETRAHYDRO 6 QUINOLYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; CALCIUM ION; CALCIUM SENSITIZER; LEVOSIMENDAN; UNCLASSIFIED DRUG;

CALCIUM CELL LEVEL; DRUG ACTIVITY; DRUG MECHANISM; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE RELAXATION; HUMAN; INOTROPISM; MYOCARDIAL DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; CALCIUM; CARDIOTONIC AGENTS; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL CONTRACTION; MYOCARDIUM; PHOSPHODIESTERASE INHIBITORS; QUINOLINES; THIADIAZINES;

EID: 0030690491     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(97)00174-0     Document Type: Review

References (109)

1. Franciosa JA. Epidemiologic patterns, clinical evaluation and long-term prognosis in chronic congestive heart failure. Am J Med 1986;80:14-21.
2. Kannel WB, Belanger JA. Epidemiology of heart failure. Am Heart J 1991;121:951-956.
3. Remes J, Reunanen A, Aromaa A, Pyorala K. Incidence of heart failure in eastern Finland: a population-based surveillance study. Eur Heart J 1992;42:287-289.
4. Parameshwar J, Shackell MM, Richardson A, Poole-Wilson PA, Sutton GC. Prevalence of heart failure in three general practices in north west London. J Gen Pract 1992;26:139-142.
5. Ho KKL, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham heart study subjects. Circulation 1993;88:107-115.
6. Packer M. Pathophysiology of chronic heart failure. Lancet 1992;340:88-92.
7. Braunwald E. Pathophysiology of heart failure, In: Braunwald E, Saunders WB, ed. Heart Disease. 4th ed. 1992;393-418.
8. Armstrong PW, Moe GW. Medical advances in the treatment of congestive heart failure. Circulation 1993;88:2941-2952.
9. Just H, Drexler H, Hasenfuss G. Pathophysiology and treatment of congestive heart failure. Cardiology 1994;84(Suppl. 2):99-107.
10. Baker DW, Konstam MA, Bottorff M, Pitt B. Management of heart failure: pharmacologic treatment. J Am Med Assoc 1994;272:1361-1366.
11. Pitt B. Pharmacologic treatment of heart failure with standard drugs. Current Opinion in Cardiol 1994;9:289-294.
12. Dargie HJ, McMurray J. Heart failure: management, drug treatment and prevention. In: Julian DG, Camm AJ, Kox KM, Hall RJC, Poole-Wilson PA, ed. Diseases of the Heart, WB Saunders 1996:536-557.
13. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986;314:1547-1552.
14. The CONSENSUS, Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429-1435.
15. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
16. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-310.
17. Feldman AM, Bristow MR, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993;329:149-155.
18. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355.
19. Withering W. An account of the foxglove and some of its medical uses: with practical remarks on dropsy and other diseases, Birmingham, 1785. Facsimile Edition, 1985.
20. Kraus F, Rudolph C, Rudolph W. Effectivity of digitalis in patients with chronic heart failure and sinus rhythm: an overview of randomised, double-blind, placebo-controlled studies. Herz 1993;18:95-117.
21. Packer M, Georghiade M, Young JB, et al for the RADIANCE study. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin converting enzyme inhibitors. N Engl J Med 1993;319:1-7.
22. Packer M, Carver JR, Rodeheffer RJ, et al for the PROMISE Study Research Group Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-1475.
23. Cowley AJ, Skene AM. Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Br Heart J 1994;72:226-230.
24. Packer M. The search for the ideal positive inotropic agent. N Engl J Med 1993;329:201-202.
25. Brenner B. Changes in calcium sensitivity at the cross-bridge level, In: Lee JA, Allen DG, ed. Modulation of cardiac calcium sensitivity: a new approach to increasing the strength of the heart. Oxford University Press, 1993:197-214.
26. Chalovich JM, Eisenberg E. Inhibition of actomyosin ATPase activity by troponin-tropomyosin without blocking the binding of myosin to actin. J Biol Chem 1982;257:2431-2437.
27. Brenner B, Schoenberg M, Chalovich JM, et al. Evidence for cross-bridge attachment in relaxed muscle at low ionic strength. Proc Natl Acad Sci USA 1982;79:7288-7291.
28. Matsubara I, Suga H, Yagi N. An X-ray diffraction study of the cross-circulated canine heart. J Physiol 1977;270:311-320.
29. 2+ on crossbridge turnover kinetics in skinned single rabbit psoas fibres: implications for regulation of muscle contraction. Proc Natl Acad Sci USA 1988;85:3265-3269.
30. 2+] in tetanized mammalian heart muscle. J Gen Physiol 1986;87:223-242.
31. Gao WD, Backx PH, Azan-Backx MD, Marban E. Myofilament sensitivity in intact versus skinned rat ventricular muscle. Circ Res 1994;74:805-814.
32. Pan BS, Solaro RJ. Calcium binding properties of troponin C in detergent skinned heart muscle fibres. J Biol Chem 1987;262:7839-7849.
33. Bremel RD, Weber A. Cooperation within actin filaments in vertebrate skeletal muscle. Nature 1972;238:97-101.
34. 2+-specific regulatory sites in skinned rabbit psoas fibres. J Biol Chem 1987;262:13627-13635.
35. Solaro RJ, Modulation of activation of cardiac myofilaments by beta-adrenergic agonists. In: Lee JA, Allen DG, eds. Modulation of cardiac calcium sensitivity: a new approach to increasing the strength of the heart. Oxford University Press, 1993:160-177.
36. Shiner JS, Solaro RJ. Activation of thin-filament-regulated muscle by calcium ion: Considerations based on nearest-neighbour lattice statistics. Proc Natl Acad Sci USA 1982;79:4637-4641.
37. i-force relationship in intact twitching cardiac muscle: direct evidence for modulation by isoproterenol and EMD 53998. Biophysical J 1995;69:189-201.
38. Allen DG, Kurihara S. Calcium transients in mammalian ventricular muscle. Eur Heart J 1980;1(Suppl A):5-15.
39. 2+ sensitivity in intact cardiac muscle, In: Lee JA, Allen DG, ed. Modulation of cardiac calcium sensitivity: a new approach to increasing the strength of the heart. Oxford University Press, 1993:242-282.
40. Allen DG, Eisner DA, Pirolo JS, Smith GL. The relationship between intracellular calcium and contraction in calcium-over-loaded ferret papillary muscles. J Physiol 1985;364:169-182.
41. 2+ dependent twitch potentiation in individual cardiac myocytes. J Gen Physiol 1988;91:133-155.
42. Opie LH, Coetzee WA, Clusin WT, Calcium ions and ventricular arrhythmias. In Parratt JR, Ed. Myocardial response to injury. New York: Macmillan Press, 1992:48-66.
43. 2+ release in the heart. Cardiovasc Res 1992;26:193-214.
44. Lee JA, Allen, DG. Altering the strength of the heart: basic mechanisms. In: Lee JA, Allen DG, ed. Modulation of cardiac calcium sensitivity: a new approach to increasing the strength of the heart. Oxford University Press, 1993:1-36.
45. Zhang R, Zhao J, Mandveno A, Potter JD. Cardiac troponin I phosphorylation increases the rate of cardiac relaxation. Circ Res 1995;76:1028-1035.
46. 2+] during inotropic interventions in isolated rat myocytes. J Physiol 1991;437:351-375.
47. 2+ as an inotropic mechanism. Circulation 1986;73(Suppl III):85-98.
48. MacFarlane NG, Miller DJ. Depression of peak force without altering calcium sensitivity by the superoxide anion in chemically skinned cardiac muscle of rat. Circ Res 1992;70:1217-1224.
49. 2+ sensitive force, stiffness and unloaded shortening velocity (Vmax) in isolated contractile structures from mammalian heart muscle. Arzneim-Forschung 1981;31:188-191.
50. 2+ binding and ATPase activity of dog cardiac myofibrils by AR-L 115 BS, a novel cardiotonic agent. Circ Res 1982;51:290-294.
51. Lues I, Siegel R, Harting J. Effect of isomazole on the responsiveness to calcium of the contractile proteins in skinned cardiac muscle fibres of various species. Eur J Pharmacol 1988;11:145-153.
52. 2+ sensitisation by the cardiotonic agent APP 201-533. Basic Res Cardiol 1989;84(Suppl 1):117-124.
53. Schlotyzik G, Salzmann R, Berthold R, et al. DPI 201-106, a novel cardiotonic agent. Combination of cAMP-independent positive inotropic, negative chronotropic, action potential prolonging and coronary dilatory properties. Naunyn-Schmiedebergs Archives of Pharmacology 1985;329:316-325.
54. Müller-Beckmann B, Freund P, Honerjager P, et al. In vitro investigations on a new positive inotropic and vasodilating agent (BM 14,478), that increases myocardial cyclic AMP content and myofibrillar calcium sensitivity. J Cardiovasc Pharmacol 1989;84(Suppl 1):117-124.
55. Jonas R, Klockow M, Lues I, Wurziger H. Stereoselectivity of the positive inotropic effects of newer diazinone cardiotonics. Bioorg Med Chem Lett 1994;4:2585-2588.
56. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 1995;77:107-113.
57. Lee JA, Ruegg JC, Allen DG. Effects of pimobendan, a novel inotropic agent, on intracellular calcium and tension in isolated ferret ventricular muscle. Clinical Sci 1989;76:609-618.
58. Fitton A, Brogden RN, Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure. Drugs and Aging 1994;4:417-441.
59. 2+ in skinned cardiac muscle. Jpn J Pharmacol 1989;50:411-419.
60. Cottney J, Logan R, Marshall R, et al. Org 30029: a new cardiotonic agent possessing both phosphodiesterase inhibitory and calcium sensitisng properties. Cardiovasc Drug Rev 1990;8:179-202.
61. Miller DJ, Steele DS. The "calcium sensitising" effects of ORG 30029 in saponin- or triton-skinned rat cardiac muscle. Br J Pharmacol 1990;100:843-849.
62. Beier N, Harting J, Jonas R, et al. The novel cardiotonic agent EMD 53998 is a potent "calcium sensitiser". J Cardiovasc Pharmacol 1991;18:17-27.
63. Kawabata Y, Endoh M. Effects of the positive inotropic agent ORG 30029 on developed force and aequorin light transients in intact canine ventricular myocardium. Circ Res 1993;72:597-606.
64. Warren SE, Kihara Y, Pesaturo J, et al. Inotropic and lusitropic effects of MCI-154 on human myocardium. J Molec Cell Cardiol 1989;21:1037-1045.
65. 2+ in isolated ferret cardiac muscle. Circ Res 1993;73:61-70.
66. Alousi AA, Stankus GP, Stuart JC, Walton LH. Characterisation of the cardiotonic effects of milrinone, a new and potent cardiac bipyridine, on isolated tissues from several animal species. J Cardiovasc Pharmacol 1983;5:804-811.
67. Lee JA, Allen DG. EMD 53998 sensitises the contractile proteins to calcium in intact ferret ventricular muscle. Circ Res 1991;69:927-936.
68. Ray KP, England PJ. Phosphorylation of the inhibitory subunit of troponin and its effect on the calcium dependence of cardiac myofibril adenosine triphosphatase. FEBS Lett 1976;70:11-16.
69. 2+ sensitisation and phosphodiesterase inhibition, reside in different enantiomers. J Cardiovasc Pharmacol 1993;21:883-892.
70. Lee JA, Shah N, White J, Orchard CH. A novel thiadiazinone derivative fully reverses acidosis-induced depression of force in cardiac muscle by a calcium sensitising effect. Clinical Science 1993;84:141-144.
71. Solaro RJ, Gambassi G, Warshaw DM, et al. Stereoselective actions of thiadiazinones on canine cardiac myocytes and myofilaments. Circ Res 1993;73:981-990.
72. Zimmermann N, Boknik P, Games E, et al. Positive inotropic effects of the calcium sensitiser CGP 48506 in guinea pig myocardium (manuscript in preparation).
73. Herold P, Herzig JW, Wenk P, et al. 5-Methyl-6-phenyl-1,3,5,6-tetrahydro-3,6-methano-1,5-benzodiazocine-2,4-dione (BA 41899): representative of a novel class of purely calcium-sensitising agents. J Med Chem 1995;38:2946-2954.
74. 2+ independent mechanisms in porcine skinned trabecula. Cardiovasc Res 1996;32:411-421.
75. Gross T, Lues I, Daut J. A new cardiotonic drug reduces the energy cost of active tension in cardiac muscle. J Molec Cell Cardiol 1993;25:239-244.
76. Wolska BM, Kitada Y, Palmiter KA, Westfall MV, Johnson MD, Solaro RJ. CGP 48506 increases contractility of ventricular myocytes and myofilaments by effects on actin-myosin reaction. Am J Physiol 1996;270:H24-H32.
77. Palmer S, Di Bello S, Herzig JW. The effects of EMD 57033 on rigor tension in porcine skinned cardiac trabecula. Eur J Pharmacol 1995;294:83-90.
78. Arner A, Strauss JD, Svensson C, Rüegg JC. Effects of troponin-I extraction with vanadate and of the calcium sensitizer EMD 53998 on the rate of force generation in skinned cardiac muscle. J Molec Cell Cardiol 1995;27:615-623.
79. Strauss JD, Zeugner C, Rüegg JC. The positive inotropic calcium sensitiser EMD 53998 antagonises phosphate action on cross-bridges in cardiac skinned fibres. Eur J Pharmacol 1992;227:437-441.
80. 2+-sensitising agent. Pflügers Archiv 1992;421:388-390.
81. Simnett SJ, Lipscomb S, Ashley CC, Mulligan IP. The effect of EMD 57033, a novel cardiotonic agent, on the relaxation of skinned cardiac and skeletal muscle produced by photolysis of diazo-2, a caged calcium chelator. Pflügers Archiv 1993;425:175-177.
82. 2+ sensitisation and phosphodiesterase inhibition depend on the same enantiomeric site. Br J Pharmacol 1996;118:2037-2044.
83. Gibbs CL. Cardiac energetics. Physiol Rev 1978;58:174-253.
84. Rüegg JC. Calcium in muscle activation: a comparative approach. Springer-Verlag, Berlin:1986.
85. Kraft T. Brenner, B. Force enhancement without changes in cross-bridge turnover kinetics: the effects of EMD 57033. Biophys J 1996;72:272-282.
86. Hasenfuss G, Holubarsch C, Just H, et al. Energetic aspects of inotropic interventions in rat myocardium. Basic Res Cardiol 1987;82(Suppl 2):251-259.
87. Hasenfuss G, Pieske B, Kretschmann B, et al. Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics. J Cardiovasc Pharmacol 1995;26(Suppl. 1):45-51.
88. Strauss JD, Bletz C, Rüegg JC. The calcium sensitiser EMD 53998 antagonises phosphate-induced increases in energy cost of isometric tension in cardiac skinned fibres. Eur J Pharmacol 1994;252:219-224.
89. de Tombe PP, Burkhoff D, Hunter WC. Effects of calcium and EMD-53998 on oxygen consumption in isolated canine hearts. Circulation 1992;86:1945-1954.
90. Grandis DJ, Delnido PJ, Koretsky AP. Functional and energetic effects of the inotropic agents EMD-57033 and BAPTA on the isolated rat heart. Am J Physiol 1995;269:C472-C479.
91. 2+ sensitisation predominantly enhances function and mechanical efficiency of stunned myocardium. Circulation 1994;90:959-969.
92. Lee JA, Allen DG. Mechanisms of acute ischemic contractile failure of the heart: role of intracellular calcium. J Clinical Investigation 1991;88:361-367.
93. 2+ sensitisers caffeine and CGP 48506 on the relaxation rate of rat skinned cardiac trabeculae. Circ Res (in press).
94. Hajjar RJ, Gwathmey JK. Calcium sensitising inotropic agnets in the treatment of heart failure: a critical view. Cardiovasc Drugs and Therapeutics 1991;5:961-966.
95. Grossman W. Diastolic dysfunction in congestive heart failure. N Engl J Med 1991;325:1557-1564.
96. Lorell BH. Significance of diastolic dysfunction of the heart. Ann Rev Med 1991;42:411-436.
97. Grossman W. Congestive heart failure: role of systolic and diastolic dysfunction. In: Gwathmey JK, Briggs GM, Allen PD, ed. Heart failure: basic science and clinical aspects. New York:Marcel Dekker, 1993.
98. Than N, Shah N, White J, Lee JA, Orchard CH. Effects of acidosis and hypoxia on the response of isolated ferret cardiac muscle to inotropic agents. Cardiovasc Res 1994;28:1209-1217.
99. Hgashiyama A, Watkins MW, Chen Z, LeWinter MM. Effects of EMD 57033 on contraction and relaxation in isolated rabbit hearts. Circulation 1995;92:3094-3104.
100. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 1993;27:341-348.
101. Eisner DA, Elliott AC, Smith GL. The contribution of intracellular acidosis to the decline of developed pressure in ferret hearts exposed to cyanide. J Physiol 1987;391:99-108.
102. Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischaemia and infarction. Physiol Rev 1989;69:1049-1169.
103. Opie LH, Coetzee WA, Clusin, WT. Calcium ions and ventricular arrhythmias. In: Parratt JR, ed. Myocardial response to injury. New York: Macmillan Press, 1992:48-66.
104. Lee JA, Allen DG. Intracellular calcium in cardiac ischaemia. Atherosclerosis Rev 1993;25:151-161.
105. Evans SJ, Levi AJ, Lee JA, Jones JV. EMD 57033 enhances arrhythmias asociated with increased wall stress in the working rat heart. Clinical Sci 1995;89:59-67.
106. Schelling P, Becker KH, Lues I, et al. In vivo characterisation of the cardiotonic action of EMD 57033, a novel drug that increases left ventricular contractility via sensitisation of the myofibrils to calcium. J Molec Cell Cardiol 1991;23(Suppl V):S69.
107. Drake-Holland AJ, Lee JA, Hynd JW, et al. Beneficial effect of the calcium sensitising drug EMD 57033 in a canine model of dilated heart failure. Clinical Sci 1997 (in press).
108. Teramura S, Yamakado T, Maeda M, Nakano T. Effects of MCI-154, a calcium sensitiser, on left ventricular systoilic and diastolic function in pacing-induced heart failure in the dog. Circulation 1997;95:732-739.
109. The PICO investigators. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 1996;76:233-231.